Menarini Entered into an Exclusive License Agreement with Astellas to Commercialize Smyraf in Taiwan and Selected South-East Asian markets
- Astellas will receive $5.91M incl. up front and milestones along with royalties on net sales of Smyraf. The companies collaborated to develop, manufacture, and commercialize Smyraf (50 & 100mg) in Taiwan for rheumatoid arthritis (RA)
- Menarini also gets an option to extend the rights to select South-East Asian markets. Smyraf is currently marketed in Japan and is indicated for the treatment of PA (incl. prevention of structural joint damage) in patients who have an inadequate response to conventional therapies
- Additionally, the product was also approved in Taiwan and has patent protection for the composition of the matter until 2032
Ref: PR Newswire | Image: Menarini
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.